MNKD to Participate in the BTIG Biotechnology Conference

[sla55]

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven Binder will participate in the BTIG Biotechnology Conference taking place on Monday, August 8 – Tuesday, August 9, 2022.

This conference is being hosted by BTIG, a global financial services firm specializing in institutional trading, investment banking, research, and related brokerage services. BTIG’s Corporate Access program hosts client events across the consumer, digital assets, energy and infrastructure, financials, healthcare, real estate, and technology sectors.

Management will be participating in one-on-one meetings throughout the event. To join the conference and arrange a meeting with management, please email [e-mail].

[uvula]

(I've made the following comment previously.)
I think it is odd that mnkd's 1 sentence summary if itself no longer mentions diabetes or afrezza.

[prcgorman2]

Aug 1, 2022 8:56:24 GMT -5 uvula said:

(I've made the following comment previously.)
I think it is odd that mnkd's 1 sentence summary if itself no longer mentions diabetes or afrezza.

Why is it odd?  They mention endocrine diseases of which diabetes is the dominant disease.  I think they're marketing themselves as a pipeline company for classes of drugs. Pipeline shop was Al Mann's vision too, so it's consistent with the company direction.

[uvula]

It is odd because as of today we are a 1 product company.

[oldfishtowner]

Aug 1, 2022 9:29:23 GMT -5 uvula said:

It is odd because as of today we are a 1 product company.

Two-product company, if you have been following the recent news.  One product in each category: endocrine and the other orphan lung.

[prcgorman2]

Aug 1, 2022 9:58:17 GMT -5 oldfishtowner said:

Aug 1, 2022 9:29:23 GMT -5 uvula said:

It is odd because as of today we are a 1 product company.

Two-product company, if you have been following the recent news.  One product in each category: endocrine and the other orphan lung.

Technically, 3 products (so far); 2 for endocrine disorders, and 1 for orphan lung diseases.  We market the first two directly, and the 3rd is a pipeline product FDA-approved for treating Pulmonary Arterial Hypertension and Interstitial Lung Disease.